Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc (NQ: MNPR )

0.6099 -0.0047 (-0.76%)
Streaming Delayed Price Updated: 10:39 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,583
Open 0.6000
Bid (Size) 0.6000 (58)
Ask (Size) 0.6099 (1)
Prev. Close 0.6146
Today's Range 0.6000 - 0.6099
52wk Range 0.2739 - 1.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+64.84%
+64.84%
1 Month
-3.50%
-3.50%
3 Month
+7.00%
+7.00%
6 Month
+97.38%
+97.38%
1 Year
-33.42%
-33.42%

More News

Read More
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Recap: Monopar Therapeutics Q4 Earnings
Via Benzinga
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Crude Oil Down 2%; Maravai LifeSciences Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Surges Over 150 Points; AerCap Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Gains Over 400 Points; Keurig Dr Pepper Shares Fall After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; US Jobless Claims Fall To 201,000
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.